Rhythm Pharmaceuticals, Inc. RYTM

RYTM Company Overview

Rhythm Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company focused on developing and commercializing therapies for rare genetic diseases of obesity caused by impairments in the melanocortin-4 receptor (MC4R) pathway. The company operates within the biotechnology and pharmaceutical industries, with a specialized emphasis on precision medicine for rare endocrinology and metabolic disorders. Its core strategy is to address severe obesity conditions that have historically lacked approved pharmacological treatments.

The company’s primary product is IMCIVREE (setmelanotide), a melanocortin-4 receptor agonist approved for chronic weight management in patients with specific rare genetic forms of obesity. Revenue is primarily generated through sales of IMCIVREE in approved indications. Rhythm Pharmaceuticals was founded in 2007 and evolved from a clinical-stage biotech into a commercial organization following U.S. and international regulatory approvals beginning in 2020, marking a transition toward global commercialization and lifecycle expansion of its lead asset.